Anticonvulsant Activity of N‐Palmitoylethanolamide, a Putative Endocannabinoid, in Mice

  title={Anticonvulsant Activity of N‐Palmitoylethanolamide, a Putative Endocannabinoid, in Mice},
  author={Didier M. Lambert and S{\'e}verine Vandevoorde and G{\'e}rald Diependaele and Sophie J. Govaerts and Annie R. Robert},
Summary:  Purpose: The purpose of this study was to evaluate in mice the anticonvulsant potential of N‐palmitoylethanolamide, a putative endocannabinoid that accumulates in the body during inflammatory processes. 
Selective Antiepileptic Effects of N‐Palmitoylethanolamide, a Putative Endocannabinoid
Whether N‐palmitoylethanolamide (PEA), a putative endocannabinoid, would be effective against kindled amygdaloid seizures was determined and the effectiveness of PEA against pentylenetetrazol (PTZ)‐induced convulsions was tested.
Pharmacology of Palmitoylethanolamide and Related Compounds
Anandamide (AEA) is an endogenous fatty acid which activates the same cannabinoid receptors as ∆9-tetrahydrocannabinol, the psychoactive substance in marijuana. In vivo, anandamide exerts a number ...
N-palmitoylethanolamide derivatives: synthesis and studies on anticonvulsant and antidepressant activities
A series novel of N-palmitoylethanolamide derivatives was synthesized and screened for their anticonvulsant and antidepressant activities. Anticonvulsant activities and neurotoxicities of compounds
The Effect of Palmitoylethanolamide Analogue, N-(2-Morpholinoethyl) Palmitoylamide on Pain Behaviour in Mice
The results demonstrated that the PEA analogue exhibit central and peripheral antinociceptive activity in a dose-dependent manner presents a novel analgesic compound that may target the endogenous cannabinoid system for treatment of analgesic disorders.
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
The endocannabinoid system : drug targets, lead compounds, and potential therapeutic applications, and possible therapeutic applications.
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review
There is lesser evidence of benefit in patients with nonpain symptoms related to depression, Parkinson disease, strokes, and autism, and further research is needed to define the palliative benefits to PEA.
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
The potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer’s disease and a single-photon emission computed tomography case study reported that a mild cognitive impairment patient, treated for 9 months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances.
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
It is concluded that although none of the PEA derivatives were dramatically more potent than PEA itself at reducing the metabolism of AEA, the lack of effect of the compounds at CB(1) and CB(2) receptors makes them useful templates for development of possible therapeutic FAAH inhibitors.


Anticonvulsant Activity of Pyrid‐3‐yl‐Sulfonyl Ureas and Thioureas
These compounds exhibited a higher protective index and potency than those of phenytoin, and additional work remains necessary, however, to determine whether BM 27 is of clinical interest.
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?
PEA is a sleep inducing lipid whose mechanism of action is far from being understood and although it does not bind with high affinity to CB1 or CB2 receptors, it exhibits some cannabimimetic actions which could be explained at least in part by entourage effects.
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Arachidonylethanolamide, an arachidonic acid derivative in porcine brain, was identified in a screen for endogenous ligands for the cannabinoid receptor. The structure of this compound, which has
Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
The metabolic pathways suggested so far to underlie the biosynthesis and inactivation of anandamide and 2-AG and the current knowledge of the chemical bases for the interactions of an andamide with proteins of the endogenous cannabinoid system characterized so far are reviewed.
The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.
Data suggest that at least one aspect of the hypnotic action of OA involves interactions with the CB1 receptor system, possibly by blocking the metabolism of the endogenous CB1 cannabinoid-1 receptor agonist anandamide.
Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors.
Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration.
Overall, milacemide, a precursor of glycine, and Z-glycine have rather similar anticonvulsant profiles in mice, which may indicate that Z- glycine acts either via a prodrug mechanism or per se via an alternative mechanism.